Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Isaacs

Showing results (51-60 of 215) with videos related to

Pageof 22
Sort By:
Progress in Clinical and Biological Research|January 1, 1990
Overview of hormonal therapy for prostate cancerH B Carter, J T Isaacs
The Journal of Urology|July 1, 1989
Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapyJ M Henry, J T Isaacs
The Prostate. Supplement|January 1, 1989
Etiology and disease process of benign prostatic hyperplasiaJ T Isaacs, D S Coffey
Advances in Pharmacology (San Diego, Calif.)|January 1, 1996
Activation of programmed (apoptotic) cell death for the treatment of prostate cancerS R Denmeade, J T Isaacs
Cancer Research|August 1, 1982
Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell lossJ E Humphries, J T Isaacs
Cancer Research|March 15, 1997
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancersI B Joseph, J T Isaacs
Urology|March 1, 1981
Control of prostate growthD S Coffey, J T Isaacs
Endocrinology|February 1, 1981
Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasiaJ T Isaacs, D S Coffey
Journal of the National Cancer Institute|November 12, 1998
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agentsI B Joseph, J T Isaacs
Seminars in Urology|November 1, 1988
Experimental and theoretical basis for hormonal treatment of prostatic cancerH B Carter, J T Isaacs
Pageof 22

Showing results (51-60 of 215) with videos related to

Sort By:
Pageof 22
Progress in Clinical and Biological Research|January 1, 1990
Overview of hormonal therapy for prostate cancerH B Carter, J T Isaacs
The Journal of Urology|July 1, 1989
Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapyJ M Henry, J T Isaacs
The Prostate. Supplement|January 1, 1989
Etiology and disease process of benign prostatic hyperplasiaJ T Isaacs, D S Coffey
Advances in Pharmacology (San Diego, Calif.)|January 1, 1996
Activation of programmed (apoptotic) cell death for the treatment of prostate cancerS R Denmeade, J T Isaacs
Cancer Research|August 1, 1982
Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell lossJ E Humphries, J T Isaacs
Cancer Research|March 15, 1997
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancersI B Joseph, J T Isaacs
Urology|March 1, 1981
Control of prostate growthD S Coffey, J T Isaacs
Endocrinology|February 1, 1981
Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasiaJ T Isaacs, D S Coffey
Journal of the National Cancer Institute|November 12, 1998
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agentsI B Joseph, J T Isaacs
Seminars in Urology|November 1, 1988
Experimental and theoretical basis for hormonal treatment of prostatic cancerH B Carter, J T Isaacs
Pageof 22